Combined inhibition of NF-κB and Bcl-2 tyiggers synergistic reduction of viability and induces apoptosis in melanoma cells

Oncology Research

Volumn 21, Issue 4, 2014, Pages 173-180

  Watanabe, Mariko ^a   Umezawa, Kazuo ^b   Higashihara, Masaaki ^a   Horie, Ryouichi ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Melanoma cells; Nuclear factor B (NF B)

Indexed keywords

CASPASE 3; DEHYDROXYMETHYLEPOXYQUINOMICIN; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OBATOCLAX; PROTEIN BCL 2; PROTEIN BCL XL; TRANSCRIPTION FACTOR RELA;

APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; MELANOMA; MELANOMA CELL; MELANOMA CELL LINE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL;

EID: 84928643467     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504014X13887748696707     Document Type: Article

References (31)

1. Hursi, E. A.; Harbour, J. W.; Cornelius, L. A. Ocular melanoma: A review and the relationship to cutaneous melanoma. Arch. Dermatol. 139:1067-1073;2003
2. Korn, E. L.; Liu, P. Y; Lee, S. J.; Chapman, J. A.; Niedzwiccki, D.; Suman, V. J.; Moon, J.; Sondak, V. K.; Atkins, M. B.; Eisenhauer, E. A.; Parulekar, W.; Markovic, S. N.; Saxman, S.; Kirkwood, J. M. Mela-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks Cor future Phase II trials. J. Clin. Oncol. 26:527-534; 2008.
3. Chapman, P. B.; Hauschild, A.; Robert, C; Haanen, J. B.; Ascierto, P.; Larkin, J.; Dummer, R.; Garbe, C; Testori, A.; Maio, M.; Hogg, D.; Lorigan, P.; Lebbe, C; Jouary, T.; Schadendorf, D.; Ribas, A.; O'Day, S. J.; Sosman, J. A.; Kirkwood, J. M.; Eggermont, A. M.; Drcno, B.; Nolop, K.; Li, J.; Nelson, B.; Hou, J.; Lee, R. J.; Flaherty, K. T.; McArthur, G. A. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364:2507-2516;2011.
4. Hodi, F. S.; O'Day, S. J.; McDermott, D. E; Weber, R. W.; Sosman, J. A.; Haanen, J. B.; Gonzalez, R.; Robert, C; Schadendorf, D.; Hassel, J. C; Akerlcy, W.; Van Den Ecrtwegh, A. J.; Lulzky, J.; Lorigan, P.; Vaubel, J. M.; Linette, G. P.; Hogg, D.; Ottensmeier, C. H.; Lebbe, C; Peschcl, C; Quirt, I.; Clark, J. I.; Wolchok, J. D.; Weber, J. S.; Tian, J.; Yellin, M. J.; Nichol, G. M.; Hoos, A.; Urba, W. J. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363:711-723; 2010.
5. Gilmore, T. D. Introduction to NF-κB: Players, pathways, perspectives. Oncogene 25:6680-6684;2006.
6. Ascierto, P. A.; Streicher, H. Z.; Sznol, M. Melanoma: A model for testing new agents in combination therapies. J. Transl. Med. 8(Arl. 38):1-7; 2010.
7. Kashani-Sabet, M.; Shaikh, L.; Miller, 3rd, J. R.; Nosrati, M.; Ferreira, C. M.; Debs, R. J.; Sagebiel, R. W. NF-κB in the vascular progression of melanoma. J. Clin. Oncol. 22:617-623; 2004.
8. Huang, S.; De Guzman, A.; Bucana, C. D.; Fidler, I. J. Level of interleukin-8 expression by metastatic human melanoma cells directly correlates with constitutive NF-κB activity. Cytokines Cell. Mol. Ther. 6:9-17; 2000.
9. Payne, A. S.; Cornelius, L. A. The role of chemokines in melanoma tumor growth and metastasis. J. Invest. Dermatol. 118:915-922; 2002.
10. Richmond, A. NF-κB, chemokinc gene transcription and tumour growth. Nat. Rev. Immunol. 2:664-674; 2002.
11. Liu, J.; Surcsh Kumar, K. G.; Yu, D.; Mollon, S. A.; McMahon, M.: Herlyn, M.; Thomas-Tikhonenko, A.; Fuchs, S. Y. Oncogenic BRAF regulates p-Trcp expression and NF-κB activity in human melanoma cells. Oncogene 26:1954-1958:2007.
12. Dhawan, P.; Richmond, A. A novel NF-κB-inducing kinase-MAPK signaling pathway up-regulates NF-κB activity in melanoma cells. J. Biol. Chem. 277:7920-7928;2002.
13. Bravo-Cuellar, A.; Hcrnandez-Flores, G.; Lerma-Diaz, J. M.; Dominguez-Rodriguez, J. R.; Jave-Suarez, L. F.; De Celis-Carrillo, R.; Aguilar-Lemarroy, A.; Gomez-Lomeli, P.; Ortiz-Lazareno, P. C. Pentoxifylline and the proleasomc inhibitor MG132 induce apoplosis in human leukemia U937 cells through a decrease in the expression of Bcl-2 and Bcl-XL and phosphorylation of p65..1. Biomed. Sci. 20(Art. 13):113; 2013.
14. Goard, C. A.; Schimmcr, A. D. An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies. Core Evid. 8:15-26; 2013.
15. Matsumoto, N.; Ariga, A.; To-E, S.; Nakamura, H.; Agata, N.; Hirano, S.; Inoue, J.; Umezawa, K. Synthesis of NF-κB activation inhibitors derived from epoxyquinomicin C. Bioorg. Med. Chem. Lett. 10:865-869; 2000.
16. Walanabe, M.; Nakashima, M.; Togano, T.; Higashihara, M.; Walanabe, T.; Umezawa, K.; Hone, R. Identification of the RelA domain responsible for action of a new NF-κB inhibitor DHMEQ. Biochem. Biophys. Res. Commun. 376:310-314; 2008.
17. Yamamoto, M.; Horie, R.; Takeiri, M.; Kozawa, I.; Umezawa, K. Inaclivation of NF-κB components by covaleni binding of (-)-dehydroxymelhylepoxyc|uinomicin to specific cysteine residues. J. Med. Chem. 51:5780-5788;2008.
18. Yin, M.; Yoshida, M. A.; Tonomura, A.; Kasuga, T. Cytogenetic studies of human malignant melanoma cell lines. Bull. Tokyo Med. Dent. Univ. 39:43-54; 1992.
19. Andrews, N. C; Faller, D. V. A rapid micropreparalion technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res. 19(9):2499;1991.
20. Horie, R.; Watanabe, T; Morishita, Y; Ito, K.; Ishida, T.; Kanegac, Y; Saito, I.; Higashihara, M.; Mori, S.; Kadin. M. E. Ligand-independenl signaling by overexpressed CD30 drives NF-κB activation in Hodgkin-Reed-Sternberg cells. Oncogene 21:2493-2503;2002.
21. Chou, T C; Talalay, P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55; 1984.
22. Kanetaka, Y; Hayashida, M.; Hoshika, A.; Yanase. N.; Mizuguchi, J. lnlerferon-alpha induces transient upregulalion of c-FLIP through NF-κB activation. Exp. Cell Res. 314:246-254:2008.
23. McNully, S. E.; Del Rosario, R.; Cen, D.; Meyskens, Jr., F. L.; Yang, S. Comparative expression of NFκB proteins in melanocytes of normal skin vs. benign intradermal naevus and human metastatic melanoma biopsies. Pigment Cell. Res. I 7:173-180; 2004.
24. Marin, Y. E.; Wall, B. A.; Wang, S.; Namkoong, J.; Marlino, J. J.; Suh, J.; Lee, H. J.; Rabson, A. B.; Yang, C. S.; Chen, S.; Ryu, J. H. Cureumin downregulates the constitutive activity of NF-κB and induces apoptosis in novel mouse melanoma cells. Melanoma Res. 17:274-283; 2007.
25. Amschler, K.; Schon, M. P.; Pletz, N.; Wallbrecht, K.; Erpenbeck, L.; Schon, M. NF-κB inhibition through proteasome inhibition or IKKβ blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways. J. Invest. Dermatol. 130:1073-1086;2010.
26. Yang, J.; Amiri, K. I.; Burke, J. R.; Schmid, J. A.; Richmond, A. BMS-345541 targets inhibitor of κB kinase and induces apoptosis in melanoma: Involvement of nuclear factor \κB and mitochondria pathways. Clin. Cancer Res. 12:950-960; 2006.
27. Perkins, N. D. The diverse and complex roles of NF-κB subunits in cancer. Nat. Rev. Cancer 12:121-132; 2012.
28. Chariot, A. The NF-κB-independent functions of IKK subunits in immunity and cancer. Trends Cell Biol. 19:404-413; 2009.
29. Dror, R.; Lederman, M.; Umezawa, K.; Barak, V.; Pe'er, J.; Chowcrs, I. Characterizing the involvement of the nuclear factor-kappa B (NFκB) transcription factor in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 51:1811-1816;2010.
30. Rapozzi, V.; Umczawa, K.; Xodo, L. E. Role of NF-κB/Snail/RKIP loop in the response of tumor cells to photodynamic therapy. Lasers Surg. Med. 43:575-585; 2011.
31. Walanabe, M.; Dewan, M. Z.; Taira, M.; Shoda, M.; Honda, M.; Sata, T; Higashihara, M.; Kadin, M. E.; Watanabe, T; Yamamolo, N.; Umezawa, K.; Horic, R. IκBα independent induction of NF-κB and its inhibition by DHMEQ in Hodgkin/Reed-Sternberg cells. Lab. Invest. 87:372-382; 2007.